Anticholinergic Burden and Botulinum Toxin Needs after Deep Brain Stimulation in Adult and Pediatric Patients with Dystonia

Document Type

Article

Publication Date

3-1-2026

Abstract

Background: Anticholinergic medications and botulinum neurotoxin injections are established treatments for dystonia, yet they carry potential side effects and practical challenges. Deep brain stimulation (DBS) is offered in case of poor response to these approaches. Objectives: To assess the need for anticholinergic medications and botulinum neurotoxin injections in adult and pediatric patients at two specialized Canadian centers before and after DBS over the past 10 years. Methods: 58 patients were included analyzing data before, 6 and 12 months after DBS. Clinical assessment included the Toronto Western Spasmodic Torticollis Rating Scale and Fahn-Marsden Dystonia Rating Scale. Anticholinergic burden was determined by the Anticholinergic Drug Scale (ADS). Results: Severity of cervical dystonia and ADS scores reduction were statistically significant after DBS. Anticholinergic medication and Botulinum Neurotoxin injections were discontinued a year after surgery in 28.8% and 72.4% of the patients, respectively. Conclusion: Simplification of anti-dystonia treatments is another added benefit of DBS.

Keywords

anticholinergic, botulinum neurotoxin, deep brain stimulation, dystonia, treatment

Publication Title

Movement Disorders Clinical Practice

ISSN

2330-1619

DOI

10.1002/mdc3.70370

Volume

13

Issue

3

First Page

774

Last Page

778

Publisher

John Wiley and Sons Inc

Share

COinS